neuroprotectants การใช้

• As of November 2014, other antioxidants are being studied as potential neuroprotectants.
• KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent  Cannabinoids as Antioxidants and Neuroprotectants ."
• The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma . . ."
• To extend the three-hour time frame, and limit brain damage in the meantime, researchers and drug companies are at work on a new class of drugs called neuroprotectants.
• In fact, many antioxidant neuroprotectants such as uric acid and NXY-059 work at the level of the endothelium and not in the brain " per se ".
• Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.
• Patients who took one of the new neuroprotectants, called citicoline, had higher scores on learning and memory tests six weeks after their strokes than others given a placebo pill, according to one study.
• In 2011, the company was granted an Exclusive License by National Institutes of Health  Office of Technology Transfer ( NIH-OTT ) for the Commercialization of patent,  Cannabinoids as Antioxidants and Neuroprotectants ."
• The results of large human trials using these new neuroprotectants, presented Saturday at a stroke meeting sponsored by the American Heart Association, were mixed; but taken together, the findings suggest that the drugs work as intended.
• Other ongoing clinical studies are aimed at the prevention and treatment of PVL : clinical trials testing neuroprotectants, prevention of premature births, and examining potential medications for the attenuation of white matter damage are all currently supported by NIH funding.
• The prospective exclusive license territory may be worldwide, and the field of use may be limited to : The development and sale of cannabinoid ( s ) and cannabidiol ( s ) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, for the treatment of hepatic encephalopathy, as claimed in the Licensed Patent Rights.
• On October 7, 2003, a U . S . patent number 6630507 entitled " Cannabinoids as Antioxidants and Neuroprotectants " was awarded to the United States Department of Health and Human Services, based on research carried out at the National Institute of Mental Health ( NIMH ), and the National Institute of Neurological Disorders and Stroke ( NINDS ).